Connor, Clark & Lunn Investment Management (CC&L)
VKTX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Viking Therapeutics VKTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7M Buy
530,607
+14,499
+3% +$468K 0.04% 361
2026
Q1 		$16.8M Sell
516,108
-2,688
-0.5% -$86.4K 0.04% 349
2025
Q4 		$18.3M Sell
518,796
-25,405
-5% -$900K 0.05% 306
2025
Q3 		$14.3M Buy
544,201
+96,984
+22% +$2.89M 0.05% 332
2025
Q2 		$11.9M Sell
447,217
-150,298
-25% -$3.96M 0.04% 356
2025
Q1 		$14.4M Buy
597,515
+222,293
+59% +$7.03M 0.06% 246
2024
Q4 		$15.1M Buy
375,222
+216,873
+137% +$12.4M 0.07% 221
2024
Q3 		$10M Buy
158,349
+108,581
+218% +$6.37M 0.05% 276
2024
Q2 		$2.64M Buy
+49,768
New +$3.26M 0.01% 583
2023
Q4 		– Sell
-76,360
Closed -$845K – 1573
2023
Q3 		$845K Sell
76,360
-121,051
-61% -$1.73M ﹤0.01% 870
2023
Q2 		$3.2M Buy
197,411
+106,985
+118% +$2.24M 0.02% 486
2023
Q1 		$1.51M Buy
90,426
+2,180
+2% +$22.5K 0.01% 624
2022
Q4 		$830K Sell
88,246
-171,641
-66% -$766K ﹤0.01% 753
2022
Q3 		$707K Buy
259,887
+37,025
+17% +$121K ﹤0.01% 733
2022
Q2 		$644K Buy
222,862
+104,156
+88% +$258K ﹤0.01% 722
2022
Q1 		$356K Buy
118,706
+79,507
+203% +$285K ﹤0.01% 844
2021
Q4 		$180K Buy
39,199
+15,249
+64% +$85.5K ﹤0.01% 991
2021
Q3 		$150K Buy
23,950
+9,939
+71% +$61.4K ﹤0.01% 962
2021
Q2 		$84K Buy
+14,011
New +$83.2K ﹤0.01% 947

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VKTX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Viking Therapeutics (VKTX) stake by 2.8% in Q2 2026, buying an estimated $468K and bringing the position to 530,607 shares worth $20.7M. The position accounts for 0.04% of the portfolio, ranked #361.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VKTX in Q2 2021 and has held it in 19 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 530,607 shares of Viking Therapeutics worth $20.7M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 14,499 Viking Therapeutics shares in Q2 2026, an estimated $468K.
  • Viking Therapeutics made up 0.04% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #361 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Viking Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.